2005•PubMedRequires access

Efficacy of rituximab in refractory polymyositis.

Olivier Lambotte, Rami R. Kotb, G. Maigné, F.–X. Blanc, Cécile Goujard, Jean François Delfraissy

Abstract

We describe the effectiveness of rituximab, an anti-B lymphocyte monoclonal antibody, in a case of refractory polymyositis with interstitial pulmonary disease and anti-Jo-1 autoantibody (antisynthetase syndrome). Rituximab was well tolerated, and its efficacy in inflammatory myositis should be evaluated.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 112 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Rituximab, Medicine, Polymyositis, Antisynthetase syndrome, Myositis, Refractory (planetary science), Autoantibody, Interstitial lung disease